Previous Article | Next Article ![]()
Journal of Clinical Microbiology, 02 1995, 270-274, Vol 33, No. 2
WG Starkey, J Newcombe, KM Corbett, KM Liu, PG Sanders and JM Best
Two glutathione S-transferase fusion proteins containing 44 (p1503) and 75
(p1509) amino acid residues of the rubella virus E1 glycoprotein were
expressed in Escherichia coli with the aim of producing a recombinant
rubella virus antigen for use in serological assays. p1503 contained three
neutralizing and hemagglutinating epitopes (G. M. Terry, L. M. Ho-Terry, P.
Londesborough, and K. R. Rees, Arch. Virol. 98:189-197, 1988); p1509
contained the putative neutralization domain described by Mitchell et al.
(L. A. Mitchell, T. Zhang, M. Ho, D. Decarie, A. Tingle, M. Zrein, and M.
Lacroix, J. Clin. Microbiol. 30:1841-1847, 1992) in addition to the three
epitopes present in p1503. Both fusion proteins were soluble and affinity
purified on glutathione- Sepharose 4B. In Western blots (immunoblots),
p1503 and p1509 reacted with human sera containing rubella virus-specific
immunoglobulin G. When used as antigens in indirect enzyme immunoassays to
detect rubella virus-specific immunoglobulin G, p1503 correctly identified
the rubella virus antibody status of 43 (76.8%) and p1509 correctly
identified that of 48 (85.7%) of 56 serum samples received for routine
rubella virus antibody screening. The results obtained with p1509 compare
well with those obtained with a latex agglutination assay.
Copyright © 1995 by the American Society for Microbiology. All rights reserved.
Use of rubella virus E1 fusion proteins for detection of rubella virus antibodies
Department of Virology, United Medical School, St. Thomas Hospital, London, United Kingdom.
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|